Related Experiment Video
Updated: Jun 29, 2026
07:16
Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
Prostate stem cell antigen: a prospective therapeutic and diagnostic target
Adam B Raff1, Andrew Gray, W Martin Kast
1Department of Molecular Microbiology & Immunology, and Norris Comprehensive Cancer Center, University of Southern California, 1450 Biggy Street, Los Angeles, CA 90033, USA.
Cancer Letters
|October 8, 2008
Summary
Prostate stem cell antigen (PSCA) is highly overexpressed in prostate cancer, making it a promising target for new diagnostic and therapeutic tools. Research highlights its correlation with clinical benchmarks and efficacy in treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cancer research focuses on identifying proteins for diagnostic, prognostic, and therapeutic applications.
- Prostate stem cell antigen (PSCA) is a cell surface antigen belonging to the Ly-6/Thy-1 family.
- PSCA is a glycosylphosphatidylinositol-anchored protein.
Purpose of the Study:
- To review the current knowledge on PSCA.
- To explore the potential role of PSCA in human prostate cancer treatment.
Main Methods:
- Literature review of studies on PSCA expression and function.
- Analysis of PSCA's correlation with clinical parameters.
- Evaluation of PSCA-targeting treatment modalities.
Main Results:
- PSCA is highly overexpressed in human prostate cancer with limited expression in normal tissues.
- PSCA expression correlates with clinical benchmarks like Gleason score and metastasis.
- Studies demonstrate the efficacy of PSCA targeting in various treatment approaches.
Conclusions:
- PSCA is an ideal target for prostate cancer diagnosis and therapy.
- Targeting PSCA shows significant potential for improving prostate cancer treatment outcomes.
